Navigation Links
Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
Date:11/15/2012

p>

Figure 22: API, North America, Revenue Split by Therapeutic Applications, (%), 2011–2017 50

Figure 23: API, the US, Revenue Analysis by Product Types, ($m), 2005–2017 53

Figure 24: API, the US, Revenue Share by Product Type, (%), 2005–2017 55

Figure 25: Synthetic API, the US, Revenue Analysis by Customer Base, ($m), 2005–2017 56

Figure 26: Synthetic API, the US, Revenue Share by Customer Base, (%), 2005–2017 58

Figure 27: Biotech API, The US, Revenue Analysis by Customer Base, ($m), 2005–2017 59

Figure 28: Biotech API, The US, Revenue Share by Customer Base, (%), 2005–2017 61

Figure 29: API, Canada, Revenue Analysis by Product Types, ($m), 2005–2017 62

Figure 30: API, Canada, Revenue Share by Product Type, (%), 2005–2017 64

Figure 31: Synthetic API, Canada, Revenue Analysis by Customer Base, ($m), 2005–2017 65

Figure 32: Synthetic API, Canada, Revenue Share by Customer Base, (%), 2005–2017 67

Figure 33: Biotech API, Canada, Revenue Analysis by Customer Base, ($m), 2005–2017 68

Figure 34: Biotech API, Canada, Revenue Share by Customer Base, (%), 2005–2017 70

Figure 35: API, South and Central America, Revenue Analysis by Product Types, ($m), 2005–2017 72

Figure 36: API, South and Central America, Revenue Share by Product Type, (%), 2005–2017 74

Figure 37: Synthetic API, South and Central America, Revenue Analysis by Customer Base, ($m), 2005–2017 75

Figure 38: Synthetic API, South and Central America, Revenue Share by Customer Base, (%), 2005–2017 77

Figure 39: Biotech API, South and Central America, Revenue Analysis by Customer Base, ($m), 2005–2017 78

Figure 40: Biotech API, South and Central America, Revenue Share by Customer Base, (%), 2005–2017 80

Figure 41: API, South and Central America, Revenue Split by Therapeu
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
2. AASLD Curriculum & Training (ACT) Launches With New Interactive HCV Education
3. Protalex, Inc. Announces Screening Of First Patients In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis
4. ActiveCare Announces Record Revenue For Quarter Ending June 30, 2012
5. Global High Potency Active Pharmaceutical Ingredients (HPAPIs) Market is Expected to Reach USD 17.5 billion in 2018: Transparency Market Research
6. Active Life Announces Launch of Next Generation BioDentTM for Life Science Research
7. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
8. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
9. Henry Schein Cares Disaster Relief Hotline is Active and Ready to Support Customers Affected by Hurricane Isaac
10. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
11. Cool Containers Introduces a Non-Dry Ice Active Container for Frozen Shipments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Israel , September 2, 2014 ... (TASE, NASDAQ: EMITF ) announced today following ... Medical Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M), a subsidiary ... on a fully diluted basis, announced that on September ... holds approximately 30.8% of the voting power ("Gamida Cell") ...
(Date:9/2/2014)... Bluegrass Vascular Technologies (BVT), ... lifesaving devices and methods for vascular access procedures, ... Niederauer , a seasoned senior medical device executive, ... of Series A financing, BVT is focused on ... Catheter System, a proprietary system that allows physicians ...
(Date:9/2/2014)... SOUTH SAN FRANCISCO, Calif. , Sept. 2, 2014 /PRNewswire/ ... announced that Bonnie H. Anderson , president and chief ... at the Morgan Stanley Global Healthcare Unplugged Conference 2014 on ... New York . The live audio ... website at http://investor.veracyte.com . Please connect to the website ...
Breaking Medicine Technology:Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 3Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... Stereotaxis, Inc. (Nasdaq: STXS ) announced today ... million credit facility, which includes a $30 million revolving facility ... term loan that matures on December 31, 2013.  The new ... Company,s previous facility that was scheduled to mature in March ...
... TARRYTOWN, N.Y. and BERLIN, Dec. 20, 2010 Regeneron ... HealthCare today announced positive top-line results for VEGF Trap-Eye ... led by Regeneron, the first of two Phase 3 ... retinal vein occlusion (CRVO).  In this trial, 56.1 percent ...
Cached Medicine Technology:Stereotaxis Completes $40 Million Credit Facility 2Stereotaxis Completes $40 Million Credit Facility 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 2Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 4Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 5Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 7Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 8Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 9
(Date:9/2/2014)... Boston, MA (PRWEB) September 02, 2014 ... normal for everyone. But sometimes the onset of irritability, ... serious condition, reports the September 2014 Harvard Health ... in response to everyday stresses. If they occur for ... functioning, it's an indication to seek help," says Dr. ...
(Date:9/2/2014)... The global market for peripheral vascular ... 2020, growing at an estimated CAGR of 7.2% from ... Grand View Research, Inc. Peripheral vascular devices such as ... used for treating peripheral arterial or coronary arterial diseases ... arteries. These devices are used to decrease the interference ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Researchers in New ... who developed mesothelioma after being exposed to asbestos-contaminated work clothes ... all the details of the report in a new article. ... at the ESI Model Hospital say their patient was ... breathlessness. Further investigation found that she had come in contact ...
(Date:9/2/2014)... Colo. (PRWEB) September 02, 2014 MyRounding, ... patient care, has been selected from a group of ... of the 2014 PrIME Digital Health Challenge. The competition ... one another, Tuesday, Sept. 9th at the CSU Denver ... 2012, MyRounding is based in Denver, Colo. The cloud-based, ...
(Date:9/2/2014)... 02, 2014 Eric Jimenez and Leah ... , a revolutionary makeup application device. Designed to improve ... innovation in the palm of women’s hands to help ... to Color Me’s success lies in its patented technology. ... rate of 15,000 pulses per minute, the device applies ...
Breaking Medicine News(10 mins):Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MyRounding Selected for Digital Health Venture Showcase Finals Top Three Startups Awarded $50,000 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3
... 2009 The first results of the first European survey ... at the 6th congress of the European Federation of Chapters ... , Previous surveys have looked at the overall management of ... study to look in detail at Breakthrough Cancer Pain (BTCP) ...
... ... relationship to offer comprehensive staffing, scheduling, and credentialing software to nurse staffing ... no additional charge. , ... Nashville, TN (Vocus) September 11, 2009 -- BlueSky Synergy, LLC (BlueSky) and People ...
... ... Yum-Yum D3 Gummies, Yum-Yum GOS Syrup (prebiotic fiber syrup), and Yum-Yum Zymes at the ... and Exhibition Center in Boston, MA, September 24-26, 2009. , ... Los Angeles, CA (PRWEB) September 11, 2009 ...
... ... dental group practice in central North Carolina, today announced the addition of Dr. Brian Cahill ... ... pleased to announce that Dr. Brian Cahill has joined their cosmetic and family dental practice. ...
... , , NEW YORK, Sept. 10 ... The Mount Sinai Medical Center describe the Community Diabetes and ... program which was designed specifically for people from the vulnerable Latino ... Twenty-five patients from The Mount Sinai Medical Center were randomly selected ...
... speed immunity, experts say , THURSDAY, Sept. 10 (HealthDay ... vaccine conducted in Australia and Britain show that a ... virus within about 10 days. , That,s a potentially ... would be needed to provide full immunity to the ...
Cached Medicine News:Health News:First results from major European patient survey show devastating impact of living with breakthrough cancer pain 2Health News:BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies 2Health News:BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies 3Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural Products Expo East Show in Boston 2Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural Products Expo East Show in Boston 3Health News:Dr. Brian Cahill Joins Research Triangle Dental 2Health News:Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Program's Graduation Ceremony on September 16th 2Health News:One Dose of Swine Flu Vaccine Offers Protection: Studies 2Health News:One Dose of Swine Flu Vaccine Offers Protection: Studies 3
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
Medicine Products: